JMP Securities reissued their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback